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ABSTRACT
Anti-angiogenic therapy is an important strategy to limit growth, development 
and expansion of solid tumors. However, resistance to VEGF-targeting agents may 
develop, due to activation of alternative pro-angiogenic pathways, indicating the 
need of multiple target strategy. Here we obtained tumor endothelial cells (TEC) 
either from total renal carcinomas or from renal cancer stem cells (CSC-TEC) and 
we tested the effect of a CD105 targeting monoclonal antibody, TRC105, alone or 
in association with anti-VEGF drugs. We demonstrated that TRC105 impaired the 
ability of TEC and CSC-TEC to organize in tubular structures, whereas it did not limit 
proliferation or survival. The combination of TRC105 with different anti-angiogenic 
drugs showed a synergistic effect of TRC105 only in combination with the tyrosine 
kinase inhibitor Sunitinib. In particular, TRC105 plus Sunitinib reduced tubulogenesis, 
proliferation and survival of CSC-TEC and tumor-derived TEC in a similar manner. At 
a molecular level, we showed that the combination of TRC105 and Sunitinib induced 
the phosphorylation of Smad 2/3 to promote endothelial cell death. Moreover, TRC105 
enhanced the inhibitory effect of Sunitinib on VEGF signaling and reduced VEGFR2-
Akt-Creb activation, suggesting a molecular cooperation between the two drugs. Our 
results highlight that the combined inhibition of VEGF and TGF-β pathway may have 
a potential use in renal cell carcinoma therapy.
INTRODUCTION
Angiogenesis is fundamental for solid tumor 
growth, development, and expansion. Tumor vessels differ 
from normal ones in the structural organization of the 
endothelium, suggesting that tumor vasculature originates 
by mechanisms other than the recruitment of blood vessels 
from pre-existing ones in adjacent tissues. One possible 
proposed mechanism is intra-tumor vasculogenesis 
[1–3], due to endothelial differentiation of cancer 
stem cells (CSC), a subpopulation of tumor cells with 
stem properties [4–7]. In vitro CSC are quiescent cells, 
capable of self-renewal and differentiation into different 
cell types, while in vivo they show tumor initiating 
properties, as CSC-derived tumors contain differentiated 
tumor cells, CSC, and endothelial cells [4, 8, 9]. Several 
groups have demonstrated that CSC differentiate into 
endothelial cells and pericytes and contribute to tumor 
vasculogenesis [9–17]. Since CSC are responsible for the 
maintenance and growth of tumors, they may represent 
a target for cancer therapy [18]. Both in healthy kidney 
and renal carcinomas the presence of mesenchymal stem 
cells expressing CD105 was observed [8]. We previously 
isolated from human renal carcinomas CD105+ CSC, that 
were able to acquire an endothelial phenotype both in 
vitro and in vivo [8, 19]. CSC-derived tumor endothelial 
cells (TEC) display increased pro-angiogenic features, 
including overexpression of pro-angiogenic receptors 
and survival [3]. This may lead to increased resistance 
to anti-angiogenic therapies. In addition, the inhibition 
of VEGF pathway may lead to VEGF-R2 and PDGFR-β 
overexpression after treatment discontinuation and 
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to tumor VEGF-independency [20]. It was therefore 
proposed that prolonged anti-angiogenic therapies may 
contribute to therapy resistance and maintain the hypoxia-
dependent CSC stemness, as observed in breast cancer 
xenotrapiants [21].
CD105, a TGF-β co-receptor over-expressed on 
proliferating endothelial cells, plays a fundamental 
regulatory role in endothelial cell activation. It is 
overexpressed on endothelial cells of healing wounds, 
developing embryos, inflammatory tissues, and solid 
tumors, being a marker of activated endothelium, since 
its vascular expression is limited to proliferating cells 
[22]. Dense CD105 expression on vessels is correlated 
with poor prognosis in many solid tumors including 
breast, lung, prostate, kidney, liver, and colon [23–25]. 
TRC105 (Carotuximab) is a chimeric immunoglobulin 
G1 monoclonal antibody that binds CD105. TRC105 
is currently being studied in a Phase 3 trial in 
combination with Pazopanib in advanced angiosarcoma 
(NCT02979899), and has been tested in multiple Phase 
1 and 2 clinical trials for the treatment of solid tumors 
in combination with different VEGF inhibitors [26–29]. 
However, the effect of TRC105 on different mechanisms of 
tumor vascularization, such as intra-tumor vasculogenesis, 
remains unknown. In the present study, we tested TRC105 
alone or in combination with different anti-angiogenic 
drugs approved for renal cell carcinoma therapy, on both 
TEC lines and CSC derived TEC isolated from renal 
cell carcinoma specimens. Finally, we investigated the 
molecular mechanisms involved in the synergistic effect 
of TRC105 and tyrosine kinase inhibition.
RESULTS
Endothelial differentiation of CSC
Renal cell carcinoma stem cells (CSC) were 
isolated from a nephrectomy specimen of renal clear 
cell canrcinoma, as previously described [8, 30, 31]. 
CD105+ CSC were sorted, cloned and characterized as 
tumor stem cells based on the following criteria: 1) were 
clonogenic, 2) expressed stem cell markers and lacked 
differentiation markers, 3) could differentiate in vitro 
into endothelial cell types, and 4) could generate in vivo 
serially transplantable tumors. These tumors, despite being 
derived from clones expressing mesenchymal markers, 
were epithelial carcinomas. CD105+/CD133- cells, 
representing the CSC population, were less than 10% 
of the total tumor population (Figure 1A). One CD105+/
CD133- clone was selected, and the presence of CD105+ 
was confimed by FACS analysis, as was the presence 
of the stem cell marker SSEA4 and the absence of the 
epithelial marker EPCAM (Figure 1A). Compared to the 
total tumor population, CD105+ CSC clone expressed the 
stem cell related genes Musashi (MSI), Vimentin (VIM) 
and OCT4-A, and lacked the expression of the epithelial 
marker E-CAD (Figure 1E). Moreover, these cells were 
able to grow as spheres in non-adherent culture conditions 
(Figure 1B). To test their tumorigenic ability, 100 cells 
were injected subcutaneously in SCID mice. After 2 
weeks, tumors were palpable in 100% of mice. In mice 
derived tumors (Figure 1C), we observed the presence 
of human vessels infiltrating the tumor (Figure 1D) as 
HLA/VWF expressing cells, suggesting an endothelial 
differentiation of CD105+ CSC. Endothelial differentiation 
of CD105+ CSC was observed in vitro by culturing the 
cells in hypoxia for 14 days, as previously described [31].
CSC-derived endothelial cells acquired the 
expression of the endothelial markers Ve-Cadherin 
(CD144), KDR (VEGF-R2), PECAM (CD31), TIE2 and 
VEGF, and lost the expression of the stem cell marker 
MSI and OCT4-A (Figure 1E and 1G).
In addition, when differentiated towards an 
endothelial state, CSC acquired the ability to form tubular-
like structures when plated in Matrigel (Figure 1F).
TRC105 impairs in vitro angiogenesis but 
not proliferation and survival of renal tumor 
endothelial cells
We evaluated the effect of different doses of 
the monoclonal antibody TRC105 on proliferation, 
survival and the ability to form tubular-like structures 
on tumor endothelial cells (TEC, previously isolated and 
characterized [32]) and cancer stem cells differentiated 
in endothelial cells (CSC-TEC) (Figure 2). TRC105 
significantly inhibited tubule-like structure formation both 
of CSC-TEC (Figure 2A and 2B) and of TEC (Figure 2E 
and 2F) in a dose-dependent manner. However, TRC105 
did not inhibit proliferation (Figure 2C and 2G) or survival 
(Figure 2D and 2H) of CSC-TEC or TEC. TRC105 had 
no effect on CD105+ undifferentiated CSC nor on CD105- 
renal carcinoma cell lines (Supplementary Figure 1).
The combination of TRC105 with Sunitinib is 
effective in inhibiting proliferation, survival and 
in vitro angiogenesis.
In order to test if the combination of TRC105 would 
increase the effect of other anti-angiogenic drugs, we 
tested four anti-angiogenic drugs in combination with 
TRC105. A dose response curve of the selected anti-
angiogenic drugs was performed and a dose with non 
significant apoptotic effect was chosen (not shown). 
We evaluated Axitinib, Cabozantinib, Sorafenib, 
Bevacizumab (Figure 3) and Sunitinib (Figure 4) alone 
and in combination with different doses of TRC105 on 
tubular-like structure formation (Figure 3A and 3D), 
proliferation (Figure 3B and 3E) and survival (Figure 3C 
and 3F). Synergy was not observed by addition of TRC105 
to Axitinib, Cabozantinib and Sorafenib, as evaluated on 
tube formation, proliferation or apoptosis. Bevacizumab 
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Figure 1: Endothelial differentiation of CSC. (A) Flow cytometry analysis of total tumor cell population after isolation and 
of CD105+/CD133- CSC. R1 represents CD105+/CD133- subpopulation from which the CSC clone was isolated. The red area shows 
binding of the specific antibody and the dark line the isotypic control. (B) Representative micrograph of CSC-derived spheres. Original 
magnification x200. (C) Hematoxylin and eosin staining of CSC-derived tumors. Original magnification x200. (D) Immunofluorescence 
micrographs of CSC-derived tumors showing the coexpression of HLA (green) and vWF (red) in vessels infiltrating the tumor. Original 
magnification x400. (E) Real time analysis showing the expression of E-Cadherin (ECAD), Musashi (MSI), Vimentin (VIM), OCT4-A, 
KDR, PECAM, TIE2, VEGF and ENG of the total tumor population (TOT) and endothelial-differentiated CSC (CSC ENDOTH DIFF) 
respect to undifferentiated CD105+/CD133- CSC clone (CD105+ CSC). Data are expressed as RQ and normalized vs GAPDH and to 
CD105+ CSC. *=p<0.05 and **=p<0.001 vs CD105+ CSC. (F) Representative micrograph of tubular structures formed by endothelial-
differentiated CSC. Original magnification x100. (G) Flow cytometry analysis of endothelial differentiated CSC showing the expression 
of TIE2, Ve-Cadherin (CD144) and PECAM (CD31). The red area shows binding of the specific antibody and the dark line the isotypic 
control.
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showed a partial synergistic effect with TRC105, at the 
maximum TRC105 concentration only (320 μg/ml), as 
the combination decreased proliferation (Figure 3E) and 
induced apoptosis (Figure 3F) on TEC. TRC105 did not 
increase the inhibitory effect of Bevacizumab on tube 
formation of both CSC-TEC and TEC. Instead, Sunitinib 
alone (0.1 μM, Figure 4) reduced tube formation, and the 
effect was significantly increased in combination with 
TRC105 (Figure 4A, 4D and 4G). Proliferating activity 
of CSC-TEC and TEC decreased in a dose-dependent 
manner when TRC105 was combined with Sunitinib (1 
μM) (Figure 4B and 4E). In addition, the percentage of 
apoptotic cells significantly increased only when both 
CSC-TEC and TEC were treated with Sunitinib (1 μM) in 
combination with TRC105 (Figure 4C and 4F). Moreover, 
the same additive effect was observed on normal human 
humbilical cord-derived endothelial cells (HUVEC), 
that showed a significant reduction of tube lenghts, 
proliferation and survival when incubated with Sunitinib 
and TRC105 (Supplementary Figure 2). No synergistic 
effect on proliferation and apoptosis was observed at the 
lower Sunitinib dose (0.1 μM) on all tumor and normal 
endothelial cells (not shown). Furthermore, TRC105 
did not exhert an additive effect on Sunitinib-induced 
apoptosis of CSC or primary renal carcinoma cell lines 
(Supplementary Figure 1).
Figure 2: Tube formation, proliferation and survival of CSC-TEC and TEC treated with TRC105. (A and E) Representative 
micrograph of tubular structures formed by CSC-TEC (A) or TEC (E) at increasing levels of TRC105 (TRC40-TRC320, corresponding 
to TRC105 from 40 to 320 μg/ml). Original magnification x100. (B and F) Tube length of CSC-TEC (B) and TEC (F) at different doses 
(40-320 μg/ml) of TRC105. Data are represented as mean ± SD of at least three independent experiments normalized to untreated cells 
(CTL). *=p<0.05 and **=p<0.001 vs CTL. (C and G) Proliferation levels of CSC-TEC (C) and TEC (G) at different doses (40-320 μg/ml) 
of TRC105. Data are represented as mean ± SD of at least three independent experiments normalized to CTL. (D and H) Percentage of 
apoptotic CSC-TEC (D) and TEC (H) treated with two different doses of TRC105 (80 and 160 μg/ml). Data are represented as mean ± SD 
of at least three independent experiments.
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TRC105 and Sunitinib combination promotes 
cell apoptosis by increasing Smad 2/3 
phosphorylation
We analyzed the effect of TRC105 alone or in 
combination with an ineffective dose of Sunitinib on the 
modulation of the expression of 86 drug targets genes 
on CSC-TEC. TRC105 alone induced the regulation of 
46 genes, while CSC-TEC treatment with Sunitinib as a 
single therapy induced the regulation of 5 genes (Figure 
5A and Supplementary Table 1). Analyzing the molecular 
function of single drug treatment with TRC105, we 
observed it affected the regulation of several serine/
threonine kinases (Figure 5B). In addition, when cells were 
treated with the combination of the two drugs, additional 
16 genes were regulated, including growth factor receptors 
and protein kinases (Figure 5A and Supplementary 
Table 1). Biologic pathway analysis of genes regulated 
by TRC105 in combination with Sunitinib (47 genes) 
showed the modulation of genes mainly involved in the 
VEGF signaling pathway (Figure 5C). We confirmed 
the VEGF pathway modulation by analysis of the KDR 
receptor following combined treatment with Sunitinib and 
TRC105. We observed a significant down-regulation of 
KDR in cells treated with the combination of the two anti-
angiogenic drugs (Figure 5D).
In order to better understand the molecular 
pathways involved in the synergistic effect of TRC105 
and Sunitinib, we evaluated the activation of VEGF and 
TGF-β intracellular pathways. In particular, we studied the 
levels of p-Smad 2/3, activated by TGF-β signalling, and 
of p-Erk, p-Akt and p-Creb, activated by VEGF (Figure 6). 
Smad 2/3 phosphorylation was highly induced by TRC105 
alone and further increased by the combination with the 
tyrosine kinase inhibitor Sunitinib (Figure 6A and 6B), 
while levels of p-Smad 1/5 did not vary in the presence 
of the TRC105 and Sunitinib (not shown). Furthermore, 
p-Akt levels were lower in the presence of TRC105 and 
significantly decreased when CSC-TEC were treated with 
Sunitinib and the combination of both (Figure 6A and 6B). 
As a consequence, the phosphorylation of the transcription 
factor Creb was decreased by the combination of the two 
drugs (Figure 6A and 6B).
We also evaluated VEGF and TGF-β intracellular 
pathway modulation by TRC105 in association with other 
tyrosine kinase inhibitors that did not show a functional 
synergistic effect (Figure 6C and 6D). We found that 
Sorafenib and Axitinib did not induce modulation of 
Akt and of the downstream Creb pathways, at variance 
of Sunitinib. Erk pathway was slightly modulated 
by Cabozantinib but the effect was reverted when in 
combination with TRC105, possibly due to Smad 2/3 
Figure 3: Tube formation, proliferation and survival of CSC-TEC and TEC treated with TRC105 in combination with 
different anti-angiogenic drugs. (A and D) Tube length of CSC-TEC (A) and TEC (D) at increasing doses of TRC (TRC80-TRC320, 
corresponding to TRC105 from 80 to 320 μg/ml) in combination with Axitinib (AXI), Cabozantinib (CABO), Sorafenib (SOR) (all 1 μM) 
and Bevacizumab (BEVA) (100 μg/ml). (B and E) Proliferation levels of CSC-TEC (B) and TEC (E) at escalating doses of TRC105 (80-
320 μg/ml) in combination with AXI, CABO, SOR and BEVA. Data are represented as mean ± SD of at least three independent experiments 
normalized to CTL and to 1. (C and F) Percentage of apoptotic CSC-TEC (C) and TEC (F) treated with AXI, CABO, SOR and BEVA 
alone or in combination with different doses of TRC105 (80-160 μg/ml). Data are represented as mean ± SD of at least three independent 
experiments normalized to untreated cells (CTL). *=p<0.05 vs CTL.
Oncotarget22685www.oncotarget.com
activation of Erk (Figure 6C and 6D). Therefore, the 
specific effect of Sunitinib on Akt pathway appears 
involved in the synergy with TRC105-dependent 
phosphorylation of Smad 2/3, resulting in a significant 
reduction of Creb levels and of endothelial cell activation 
(Figures 6A, 6B and 7), hence, promoting endothelial cell 
death.
DISCUSSION
Angiogenesis is a fundamental process required for 
the growth, development and expansion of solid tumors. In 
this work, we generated from renal cell carcinoma CSC-
derived and tumor-derived endothelial cells expressing 
the surface glycoprotein CD105 (Endoglin) and tested 
the effect of TRC105, a CD105 monoclonal antibody, on 
the angiogenic properties of these tumor endothelial cells 
(TEC). We found that TRC105 alone inhibited the ability 
of TEC and CSC-TEC to organize in tubular structures, 
whereas it did not impair their proliferation or survival. 
Moreover, TRC105 increased the effect of the tyrosine 
kinase inhibitor Sunitinib in inhibiting tumor endothelial 
proliferation, survival and new vessel formation. The 
analysis of the molecular mechanisms involved in the 
combined effect of the two drugs showed simultaneous 
inhibition of TGF-β and VEGF signaling pathways with 
Figure 4: TRC105 in combination with Sunitinib inhibits tube formation, proliferation and survival of CSC-TEC 
and TEC. (A and D) Tube length of CSC-TEC (A) and TEC (D) at increasing levels of TRC105 (TRC80 and TRC160, corresponding to 
TRC105 80 and 160 μg/ml) in combination with tyrosine kinase Sunitinib (SUN, 0.1μM). Data are represented as mean ± SD of at least 
three independent experiments normalized to untreated cells (CTL). **=p<0.001 vs CTL; $=p<0.05 and $$=p<0.001 vs SUN. (B and E) 
Proliferation levels of CSC-TEC (B) and TEC (E) at escalating doses of TRC105 (40-320 μg/ml) in combination with SUN (1μM). Data 
are represented as mean ± SD of at least three independent experiments normalized to CTL and to 1. *=p<0.05 and **=p<0.001 vs CTL; 
$=p<0.05 vs SUN. (C and F) Percentage of apoptotic CSC-TEC (C) and TEC (F) treated with SUN alone (1μM) or in combination with 
two different doses of TRC105 (80-160 μg/ml). Data are represented as mean ± SD of at least three independent experiments. **=p<0.001 
vs CTL; $=p<0.05 vs SUN. (G) Representative micrograph of tubular structures formed by CSC-TEC or TEC treated with SUN (0.1μM) in 
combination with increasing levels of TRC (80-160 μg/ml). Original magnification x100.
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activation of Smad 2/3 apoptotic pathway and inhibition 
of Akt-dependent Creb activity, suggesting a synergism in 
promoting endothelial cell death.
TEC are the main targets of anti-angiogenic therapy 
[1] and may derive from recruited endothelial cells or 
from intra-tumor vasculogenesis due to endothelial 
differentiation of CSC [8]. However, the clinical activity of 
anti-angiogenic drugs has not been as robust as predicted 
by preclinical models. This may reflect angiogenic 
features of TEC compared to normal endothelium, and to 
the development of drug resistance from the activation of 
alternative intracellular pathways [32]. Indeed, endothelial 
cells treated with VEGF inhibitors overexpress angiogenic 
receptors possibly including CD105 [20]. Heterozygous 
CD105 expression and conditional knock-out of CD105 
sensitize tumors to VEGF inhibition, suggesting that 
Figure 5: Molecular analysis of CSC-TEC treated with TRC105 and Sunitinib alone or in combination. (A) Funrich 
analysis of regulated genes of CSC-TEC treated with TRC105 (160 μg/ml), Sunitinib 0.1μM (SUN) or the combination of the two drugs 
(TRC105+SUN). (B) Molecular function analysis of the genes regulated by the single therapy treatment with TRC105 on CSC-TEC. (C) 
Biological pathway analysis of CSC-TEC genes regulated by the combination of TRC105 and SUN. (D) Real time analysis of KDR mRNA 
expression in CSC-TEC treated with TRC105 alone, SUN, or the combination of both. **=p<0.001 vs CTL.
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CD105 may be a mechanism of VEGF resistance [33]. 
TRC105 is a new anti-angiogenic monoclonal antibody 
targeting CD105. Indeed, CD105 is highly expressed on 
proliferating endothelial cells [23] and is of relevance in 
renal cell carcinoma, being expressed by CSC and CSC-
derived TEC. In the present study, we confirmed our 
previous results [8, 31] showing that renal cell carcinoma-
derived CD105+ cells possess stem cell properties, such as 
clonogenicity, sphere formation ability, in vivo tumorigenic 
ability and endothelial cell differentiation capability. We 
therefore investigated the effect of the CD105 targeting 
drug TRC105 on the angiogenic properties of renal 
TEC. Previous studies showed that CD105 inhibition 
affects tube formation but not the proliferation of normal 
endothelial cells (HUVEC) [34]. Our results confirmed 
that TRC105 alone also significantly inhibited tube 
formation but not viability of TEC. Moreover, TRC105 
potentiated the effect of the anti-VEGF drug Sunitinib to 
inhibit proliferation, survival and tube formation of these 
cells. The combination of tyrosine kinase inhibition and 
TRC105 demonstrated a similar anti-angiogenic effect 
on normal endothelial cells, as reported [35]. This was 
notable given TEC are less sensitive to chemotherapy than 
normal endothelial cells [32]. Surprisingly, a combinatory 
effect was not observed on TEC with the anti-angiogenic 
drugs Axitinib, Sorafenib and Cabozantinib. This may 
suggest a specific interaction of the intracellular pathways 
blocked by Sunitinib and TRC105. The combined effect 
of tyrosine kinase and TGF-β inhibition was previously 
confirmed by in vivo experiments where the combination 
was effective in decreasing tumor vascular density, tumor 
growth and metastasis [33, 35]. TGF-β may induce both 
Figure 6: Western blot analysis on CSC-TEC treated with TRC105 alone or in combination with Axitinib, Sorafenib, 
Cabozantinib and Sunitinib. (A) Representative micrographs of western blot on CSC-TEC treated with TRC105 (160 μg/ml) alone or 
in combination with Sunitinib (1 μM), using antibodies against p-Erk, p-AKT, p-Smad 2/3 and p-Creb. (B) Western blot analysis showing 
the quantification of the protein levels of CSC-TEC treated with TRC105 (160 μg/ml) alone or in combination with Sunitinib (1 μM), 
normalized to Vinculin and to CTL. The relative expression of p-Erk and p-Akt were also normalized to basal Erk and Akt. *=p<0.05 and 
**=p<0.001 vs CTL; $=p<0.005 and $$=p<0.001 vs TRC. (C) Representative micrographs of western blot on CSC-TEC treated with TRC105 
(160 μg/ml) alone or in combination with Axitinib (AXI), Sorafenib (SOR) and Cabozantinib (CABO) (all 1 μM), using antibodies against 
p-Erk, p-AKT, p-Smad 2/3 and p-Creb. (D) Western blot analysis showing the quantification of the protein levels of CSC-TEC treated with 
with TRC105 (160 μg/ml) alone or in combination with Axitinib (AXI), Sorafenib (SOR) (all 1 μM), normalized to Vinculin and to CTL. 
The relative expression of p-Erk and p-Akt were also normalized to basal Erk and Akt. *=p<0.05 and **=p<0.001 vs CTL; $=p<0.005 vs 
TRC.
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proliferation and apoptosis of endothelium, and CD105 
acts as TGF-β co-receptor that influences the downstream 
pathways (Figure 7). In particular, activation of TGF-β 
receptor complex in the presence of CD105 results in 
phosphorylation of Smad 1/5, which activates cell growth 
[23]. In the absence of CD105, TGF-β signaling leads to 
Smad 2/3 phosphorylation and endothelial cell apoptosis 
[23]. In the present study, we found, accordingly, that 
CD105 inhibition by TRC105 on CSC-TEC promoted 
the phosphorylation of Smad 2/3 which, once in the 
nucleus, induces endothelial cell death. In addition, this 
effect was significantly increased when Sunitinib was 
used in combination with TRC105. The efficacy of this 
combination appears different from that observed in normal 
endothelial cells, where TRC105 blocked the TGF-β 
receptor-dependent phosphorylation of Smad 1/5 but it 
had no influence on Smad 2/3 [34]. Interestingly, TRC105 
also enhanced the effect of Sunitinib on VEGF signaling, 
suggesting a molecular cooperation between the two drugs 
(Figure 7). It was recently reported that the combination of 
TRC105 and the tyrosine kinase inhibitor SU5416 might 
impair the direct interaction between CD105 and KDR 
[36]. Indeed, we show that the combination of TRC105 
and Sunitinib decreased KDR levels and affected the 
phosphorylation of the VEGF-dependent transcription 
factor Creb in parallel to reduction of Akt phosphorylation. 
This may be reinforced by the additional effect of TRC105-
mediated phosphorylation of Smad 2/3 on a direct Akt 
inhibition, as described [37]. Of note, the molecular 
pathways modulated by TRC105 and tyrosine kinase 
inhibition appear specific for the drug in use. In fact, in 
parallel with the absence of a functional synergistic effect, 
other tyrosine kinase inhibitors did not induce reduction 
of Akt-Creb pathway. Indeed, Cabozantinib, Axitinib 
and Sorafenib preferentially led to a slight modulation of 
the VEGF-R dependent Erk signaling pathway in TEC. 
The absence of synergy could be possibly explained by 
the described positive interaction of Erk on the TGF-β 
pathway, as reduced Erk activity could decrease Smad 2/3 
phosphorylation and viceversa [38, 39]. No modulatory 
effect on Erk phosphorylation was instead observed in 
the presence of Sunitinib, as described in prostate tumor 
endothelial cells [40]. In conclusion, our results highlight 
a synergistic effect of TRC105 in combination with 
Sunitinib on tumor vascularization, proliferation and 
survival of CSC-TEC and TEC. This effect was greater 
than that observed on non-tumor endothelium and could 
be possibly due to high CD105 expression or activity. 
At a molecular level, we demonstrated that TRC105 and 
Sunitinib cooperate to promote cell apoptosis by inducing 
Smad 2/3 phosphorylation, through the TRC105-mediated 
inhibition of CD105, and by reducing the tyrosine 
Figure 7: Molecular pathways involved in the pharmacological inhibition of CD105 by TRC105 and of KDR by 
Sunitinib. In endothelial cells (EC), TRC105 blocks CD105 favouring the TGF-ß receptor/ALK5 complex signaling. This complex 
phosphorylates and activates Smad 2/3 which can translocate in the nucleus leading to endothelial cell apoptosis. Sunitinib inhibits the 
signaling pathway of VEGF receptor 2 (KDR), resulting in a reduced Akt activity. In the presence of both drugs, Akt is synergistically 
inhibited by Sunitinib and by Smad 2/3 resulting in a reduced phosphorylation of the transcription factor Creb, involved in cell activation. 
Other tyrosine kinase inhibitors (Axitinib, Sorafenib and Cabozantinib), show a predominant modulation of the Erk pathway and do not 
affect Creb phosphorylation. No synergistic effect of TRC105 is present in combination with Axitinib, Sorafenib and Cabozantinib on 
VEGF receptor signaling pathways.
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kinase activity of KDR by Sunitinib. Both the decreased 
phosphorylation of Creb and the increased activity of 
Smad 2/3 may limit endothelial angiogenesis and induce 
apoptosis of endothelial cells (Figure 7). Interaction of 
VEGF and CD105 signaling was recently reported in 
vitro in endothelial cells [36] and in vivo in mouse models 
where CD105 targeting inhibited VEGF-R signaling [36] 
and altered the response of VEGF-R to VEGF [41]. Our 
results support this finding and indicate that the combined 
inhibition of these two pathways may have a potential use 
in renal cell carcinoma therapy.
MATERIALS AND METHODS
Cells isolation and characterization
Renal cell carcinoma stem cells (CSC) and primary 
carcinoma cell lines were isolated and characterized 
as previously described [8, 30, 31]. Briefly, CSC were 
obtained from specimens of renal cell carcinomas from 
patients undergoing radical nephrectomy according to the 
Ethics Committee of the S. Giovanni Battista Hospital of 
Torino, Italy (n. 168/2014). Magnetically sorted CD105+ 
CSC were cultured in the presence of the expansion 
medium, consisting of DMEM LG (Invitrogen), with 
insulin-transferrin-selenium, 10-9 M dexamethasone, 100 
U penicillin, 1000 U streptomycin, 10 ng/ml EGF (all from 
Sigma-Aldrich) and 5% fetal calf serum (FCS) (Sigma-
Aldrich) [8]. A CD105+ clonal renal cell carcinoma stem 
cell line was selected and used for all the experiments. 
Renal carcinoma primary cell lines were grown in DMEM 
and 10% FSC and CD105 expression was ranged from 2 
to 20% (mean 11.49 %). TEC and HUVEC were obtained 
from renal cell carcinoma and from the umbilical vein 
respectively [32]. All endothelial cells were maintained in 
culture in EndoGRO MV-VEGF medium containing 10% 
FCS.
Sphere formation
To grow CSC in non-adhesive condition as floating 
spheres, cells were plated at 1×105 cells/mL in serum-free 
DMEM-F12 (Cambrex BioScience), supplemented with 
10 ng/mL bFGF, 20 ng/mL EGF, 5 μg/mL insulin, and 
0.4% bovine serum albumin (all from Sigma-Aldrich), as 
described [8, 31].
Cytofluorimetric analysis
For cytofluorimetric analysis, cells were detached 
using a non enzymatic cell dissociation solution (Sigma-
Aldrich) and resuspended in PBS 0.1% BSA (Sigma-
Aldrich) and incubated with antibodies. The following 
antibodies, conjugated with fluorescein isothiocyanate 
(FITC), phycoerythrin (PE) or allophycocyanin (APC), 
were used: CD105, CD133, EPCAM, CD31, TIE-2, 
CD144 (Miltenyi Biotech) and SSEA4 (R&D).
Endothelial differentiation of CSC
For endothelial differentiation, CSC were plated at 
a density of 50.000 cells/well into 6-well culture plated 
coated with Endothelial Cell Attachment Factor (Sigma-
Aldrich), in EndoGRO (Merck Millipore) and maintained 
in hypoxia (1% O2 and 5% CO2) in hypoxia chambers 
(Stem Cells Technologies) for 14 days, as previously 
described [31]. CSC-derived TEC were maintained in 
culture for further 20 passages without observing any loss 
of phenotype.
RNA isolation and Real time PCR
Total RNA was isolated from different cell 
preparations using Trizol Reagent (Ambion) according 
to the manufacturer’s protocol. RNA was then quantified 
spectrophotometrically (Nanodrop ND-1000). For gene 
expression analysis, quantitative real-time PCR was 
performed. Briefly, first-strand cDNA was produced 
from 200 ng of total RNA using the High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems). 
Real-time PCR experiments were performed in 20-μl 
reaction mixture containing 5 ng of cDNA template, the 
sequence-specific oligonucleotide primers (purchased 
from MWG-Biotech) and the Power SYBR Green PCR 
Master Mix (Applied Biosystems). GAPDH or TATA-
binding protein (TBP) mRNA were used to normalize 
RNA inputs. Fold change expression respect to control 
was calculated for all samples. The sequence-specific 
oligonucleotide primers used are GAPDH: forward, 
5’-TGGAAGGACTCATGACCACAG T-3’ and reverse, 
5’-CATCACGCCACAGTTTCCC-3’; E-CAD: forward 
5’-GCATTGCCACATACACTCTCTTCT-3’, reverse 
5’-GCTTGTTGTCATTCTGATCGGTTA-3’; MSI1: 
forward 5’-TTGGGAAGGTGGACGACG-3’, reverse 
5’-CTCCACGATGTCCTCACTCTCA; VIM: forward, 
5’-GGAACAGCA TGTCCAAAT CGA T-3’, reverse 
5’-CAGCAAACTTGGATTTGTACCATT-3’; OCT4-A: 
forward 5’-AGCAGGAGTCGGGGTGG-3’, reverse, 
5’-CTGGGACTCCTCCGGGTT-3’; KDR: forward 
5’-GAACATTTGGGAAATCTCTTGCA-3’, reverse 
5’-AGTCCAGAATCCTCTTCCATGCT-3’; PECAM: 
forward 5’-TGACAGTCAGAGTCATTCTTGCC-3’, 
reverse 5’-GGCTTTCCTCAGAAAATAACATTTG-3’; 
TIE2: forward 5’-CCCCTATGGGTGTTC-3’, reverse 
GCTTACAATCTGGCC-3’; VEGF: forward 5’-AT
GAACTTTCTGCTCTCTTGGGTGC-3’, reverse 
5’-TGATTCTGCCCTCCTCCTTCTGC-3’; ENG: 
forward 5’-TCACCACAGCGGAAAAAGG-3’, reverse 
5’-GACACTCTGACCTGCACAAAGC-3’.
CSC tumorigenic ability
In order to evaluate the vasculogenic potential of 
CSC, cells were implanted subcutaneously into SCID mice 
(Charles River) within growth factor–reduced Matrigel 
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(BD Biosciences). Briefly, 1×103 CD105+ CSC were re-
suspended in 75 μl DMEM plus 125 μl of Matrigel at 4°C. 
Cells were injected subcutaneously into the left back of 
SCID mice (n=6). After 40 days, mice were sacrificed, and 
tumors recovered and processed for histology.
Immunofluorescence
Immunofluorescence was performed on cryostatic 
sections of recovered CSC tumors for HLA class I polyclonal 
Ab and anti-human vWF (all from BioLegend). Sections 
were permeabilized with PBS-0.2% Triton for 6 minutes 
at 4°C. Alexa Fluor Texas Red goat anti-rabbit IgG and 
Alexa Fluor 488 goat anti-mouse IgG (all from Molecular 
Probes) were used as secondary antibody. Hoechst 33258 dye 
(Sigma-Aldrich) was added for nuclear staining. Confocal 
microscopy analysis was performed using a Zeiss LSM 5 
Pascal model confocal microscope (Carl Zeiss).
Anti-angiogenic drugs and reagents
Sunitinib malate, Cabozantinib, Sorafenib and 
Axitinib (Sigma-Aldrich) were resuspended in DMSO to a 
final concentration of 10 mM and stocked according to the 
manufacturer’s instructions. Bevacizumab was purchased 
from Genentech and stored at +4°C. TRC105 was supplied by 
Tracon Pharmaceuticals, San Diego, CA and stored at +4°C.
Proliferation
For proliferation assay, cells were plated in growth 
medium at a concentration of 2000 TEC-cells/well, 4000 
CSC-derived TEC-cells/well in a 96-multiwell plate and 
left adhere overnight. The day after the culture medium 
was removed and a new medium containing different 
concentrations of drugs was added to the cells. DNA 
synthesis was detected after 48h as incorporation of 
5-bromo-2-deoxyuridine (BrdU) using an enzyme-linked 
assay kit (Chemicon). Data are expressed as the mean ± 
SD of the media of absorbance of at least three different 
experiments, normalized to control (not treated cells).
Apoptosis
Annexin V assay was performed using the Muse™ 
Annexin V & Dead Cell Kit (Millipore), according to the 
manufacturer’s recommendations. Briefly, 25×103 cells 
were incubated with different concentrations of drugs for 
72 hours. Cells were then detached and resuspended in 
Muse™ Annexin V & Dead Cell Kit, and the percentage 
of apoptotic cells (Annexin V +) was detected.
Tubulogenesis
In vitro formation of capillary-like structures was 
done on growth factor–reduced Matrigel (BD Biosciences). 
Cells (25×103 cells per well) were seeded onto Matrigel- 
coated wells in EndoGRO MV-VEGF medium containing 
10% FCS with or without TRC105, the indicated anti-
angiogenic drug or the combination of both. Cells were 
periodically observed with a Nikon inverted microscope and 
experimental results recorded after 24 hours. Image analysis 
was performed with the ImageJ. Data were expressed as 
the mean ± SD of tube length in arbitrary units per field, 
normalized to untreated cells
Drug targets array
Gene expression profiling was performed on tubule-
like structures formed by 150×103 CSC-TEC treated with 
vehicle (CTL), TRC105 (160 μg/ml), Sunitinib (0.1 μg/
ml), or TRC105 and Sunitinib, using the RT2 Profiler™ 
PCR Array Human Cancer Drug Targets (PAHS 507Z, 
SA Biosciences). 200 ng of cDNA (synthesized using 
the RT2 First Strand kit (SABiosciences) according to 
manufacturer’s instructions) were loaded for each CSC-
TEC sample. The expression profile of 84 key drug targets 
genes was analyzed. Changes in the gene expression of 
treated, CSC-TEC were reported as a fold increase/
decrease ±SD respect to untreated cells. Transcripts 
with a fold increase or decrease ≥2 were used for further 
investigation using Funrich V3 Software.
Protein extraction and western blot
For protein analysis, cells were incubated with 
vehicle (CTL), TRC105 (160 μg/ml), Sunitinib (0.1 μg/
ml), or TRC105 and Sunitinib for 3h and lysed at 4°C 
for 30 min in RIPA buffer (20 nM Tris·HCl, 150 nM 
NaCl, 1% deoxycholate, 0.1% SDS, 1% Triton X-100, 
pH 7.8) supplemented with protease and phosphatase 
inhibitors cocktail and PMSF (Sigma-Aldrich). Aliquots 
of the cell lysates containing 30 μg protein, as determined 
by the Bradford method, were run on 4-20%(Biorad) 
SDS-PAGE under reducing conditions and blotted onto 
PVDF membrane filters using the iBLOT system (Life 
Technologies). For Western blot analysis, anti-pCreb, 
anti-Creb, anti-pErk, anti-Erk, anti-pSmad 2/3, anti-pAkt, 
anti-Akt and anti-Vinculin Abs (all from Cell Signaling 
Technology) were used. Data are expressed as mean ± SD 
of the band intensity normalized with vinculin of three 
independent experiments.
Statistical analysis
Statistical analysis was performed by using the 
Student t test, or ANOVA with Dunnet’s multi-comparison 
tests, as appropriate. A p value of p<0.05 was considered 
significant.
Abbreviations
ENG= Endoglin, TEC= tumor endothelial cells 
(deriving from total renal carcinomas), CSC= cancer stem 
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cells, CSC-TEC= tumor endothelial cells deriving from 
cancer stem cells, VEGF= vascular endothelial growth 
factor, VEGF-R= vascular endothelial growth factor-
receptor, KDR= kinase insert domain receptor (VEGF-R2).
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